sequenom inc (SQNM:NASDAQ GS)
Harry F. Hixson Jr., Ph.D.
Chairman of The Board, Sequenom Inc.
|Age||Total Calculated Compensation||This person is connected to 32 board members in 3 different organizations across 7 different industries.|
See Board Relationships
As of Fiscal Year 2013
Dr. Harry F. Hixson, Jr., Ph.D. served as the Chief Executive Officer of Sequenom Inc. from September 28, 2009 to June 10, 2014. Dr. Hixson served as an Interim Chief Executive Officer of Sequenom Inc. Dr. Hixson Co-founded BrainCells Inc. and served as its Chief Executive Officer from July 2004 to September 2005. He served as the Chief Executive Officer of Elitra Pharmaceuticals Inc., from February 1998 to May 2003 and served as its President from June 1998 to May 2003. ...
3595 John Hopkins CourtPhone: 858-202-9000
San Diego, California 92121
Board Members Memberships*
Former Chairman of the Board, Chief Executive Officer and President
Former Chairman, Chairman of Nominating and Corporate Governance Committee and Member of Compensation Committee
Chairman of The Board
Independent Director, Chairman of Science Committee and Member of Corporate Governance & Nominating Committee
Former Director and Member of Audit Committee
Former Director, Member of Audit Committee and Member of Compensation Committee
The University of Chicago
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|John C. Martin Ph.D.||Chairman and Chief Executive Officer|
Gilead Sciences Inc.
|John C. Lechleiter Ph.D.||Chairman, Chief Executive Officer and President|
Eli Lilly and Company
|Erez Vigodman||Chief Executive Officer, President, Director and Member of Finance & Invesment Committee|
Teva Pharmaceutical Industries Limited
|Lars Rebien Sørensen||Chief Executive Officer and Member of Executive Management|
Novo Nordisk A/S
|Richard A. Gonzalez||Chairman, Chief Executive Officer and Chairman of Executive Committee|
|$1.6M||Compensation as of Fiscal Year 2014.|